161 related articles for article (PubMed ID: 37813297)
1. Impact of Cell-Debris and Room-Temperature Storage on Urine Circulating Tumor DNA from Hepatocellular Carcinoma.
Kim AK; Lin SY; Wang Z; Luu H; Hamilton JP; Song W; Su YH
J Mol Diagn; 2023 Dec; 25(12):913-920. PubMed ID: 37813297
[TBL] [Abstract][Full Text] [Related]
2. Novel urine cell-free DNA methylation markers for hepatocellular carcinoma.
Lin SY; Xia W; Kim AK; Chen D; Schleyer S; Choi L; Wang Z; Hamilton JP; Luu H; Hann HW; Chang TT; Hu CT; Woodard A; Gade TP; Su YH
Sci Rep; 2023 Dec; 13(1):21585. PubMed ID: 38062093
[TBL] [Abstract][Full Text] [Related]
3. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
[TBL] [Abstract][Full Text] [Related]
6. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
7. Urine DNA biomarkers for hepatocellular carcinoma screening.
Kim AK; Hamilton JP; Lin SY; Chang TT; Hann HW; Hu CT; Lou Y; Lin YJ; Gade TP; Park G; Luu H; Lee TJ; Wang J; Chen D; Goggins MG; Jain S; Song W; Su YH
Br J Cancer; 2022 Jun; 126(10):1432-1438. PubMed ID: 35046521
[TBL] [Abstract][Full Text] [Related]
8. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
Oncology; 2021; 99(2):114-123. PubMed ID: 32998139
[TBL] [Abstract][Full Text] [Related]
9. Circulating Cell-Free DNA and DNA Integrity as Molecular Diagnostic Tools in Hepatocellular Carcinoma.
Elzehery R; Effat N; El Farahaty R; Elsayed Farag R; Abo-Hashem EM; Elhelaly R
Am J Clin Pathol; 2022 Aug; 158(2):254-262. PubMed ID: 35403666
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA.
Hlady RA; Zhao X; Pan X; Yang JD; Ahmed F; Antwi SO; Giama NH; Patel T; Roberts LR; Liu C; Robertson KD
Theranostics; 2019; 9(24):7239-7250. PubMed ID: 31695765
[TBL] [Abstract][Full Text] [Related]
11. Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma.
Oussalah A; Rischer S; Bensenane M; Conroy G; Filhine-Tresarrieu P; Debard R; Forest-Tramoy D; Josse T; Reinicke D; Garcia M; Luc A; Baumann C; Ayav A; Laurent V; Hollenbach M; Ripoll C; Guéant-Rodriguez RM; Namour F; Zipprich A; Fleischhacker M; Bronowicki JP; Guéant JL
EBioMedicine; 2018 Apr; 30():138-147. PubMed ID: 29627389
[TBL] [Abstract][Full Text] [Related]
12. New method to preserve the original proportion and integrity of urinary cell-free DNA.
Li P; Ning J; Luo X; Du H; Zhang Q; Zhou G; Du Q; Ou Z; Wang L; Wang Y
J Clin Lab Anal; 2019 Feb; 33(2):e22668. PubMed ID: 30175467
[TBL] [Abstract][Full Text] [Related]
13. A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma.
Kim SC; Kim DW; Cho EJ; Lee JY; Kim J; Kwon C; Kim-Ha J; Hong SK; Choi Y; Yi NJ; Lee KW; Suh KS; Kim W; Kim W; Kim H; Kim YJ; Yoon JH; Yu SJ; Kim YJ
Mol Cancer; 2023 Oct; 22(1):164. PubMed ID: 37803338
[TBL] [Abstract][Full Text] [Related]
14. Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma.
Lu CY; Chen SY; Peng HL; Kan PY; Chang WC; Yen CJ
Oncotarget; 2017 Jan; 8(4):6406-6418. PubMed ID: 28031532
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma.
Yan L; Chen Y; Zhou J; Zhao H; Zhang H; Wang G
Int J Infect Dis; 2018 Feb; 67():92-97. PubMed ID: 29229500
[TBL] [Abstract][Full Text] [Related]
16. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
von Felden J; Craig AJ; Garcia-Lezana T; Labgaa I; Haber PK; D'Avola D; Asgharpour A; Dieterich D; Bonaccorso A; Torres-Martin M; Sia D; Sung MW; Tabrizian P; Schwartz M; Llovet JM; Villanueva A
Oncogene; 2021 Jan; 40(1):140-151. PubMed ID: 33097857
[TBL] [Abstract][Full Text] [Related]
17. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
18. Early detection of hepatocellular carcinoma via no end-repair enzymatic methylation sequencing of cell-free DNA and pre-trained neural network.
Deng Z; Ji Y; Han B; Tan Z; Ren Y; Gao J; Chen N; Ma C; Zhang Y; Yao Y; Lu H; Huang H; Xu M; Chen L; Zheng L; Gu J; Xiong D; Zhao J; Gu J; Chen Z; Wang K
Genome Med; 2023 Nov; 15(1):93. PubMed ID: 37936230
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma detection via targeted enzymatic methyl sequencing of plasma cell-free DNA.
Guo P; Zheng H; Li Y; Li Y; Xiao Y; Zheng J; Zhu X; Xu H; He Z; Zhang Q; Chen J; Qiu M; Jiang M; Liu P; Chen H
Clin Epigenetics; 2023 Jan; 15(1):2. PubMed ID: 36600275
[TBL] [Abstract][Full Text] [Related]
20. Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma.
Lee HW; Kim E; Cho KJ; Park HJ; Seo J; Lee H; Baek E; Choi JR; Han KH; Lee ST; Park JY
Liver Int; 2022 Oct; 42(10):2317-2326. PubMed ID: 35776657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
